Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, R...
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
About this item
Full title
Author / Creator
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Journal title
Language
English
Formats
Publication information
Publisher
United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects
More information
Scope and Contents
Contents
Tenapanor is a first-in-class, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger NHE3. This study assessed the efficacy and safety of tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).
In this phase 2, double-blind study, patients with IBS-C (Rome III criteria) were randomized (1:1:1:1)...
Alternative Titles
Full title
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5418559
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5418559
Other Identifiers
ISSN
0002-9270
E-ISSN
1572-0241
DOI
10.1038/ajg.2017.41
